RARE Daily

Agios Names Brian Goff as CEO

July 13, 2022

Agios Pharmaceuticals named rare disease drug veteran Brian Goff as CEO to replace Jackie Fouse, who will transition to the role of chair of the board of directors

Photo: Jackie Fouse, newly appointed chair and outgoing CEO of Agios

Current Agios chairman, David Schenkein, will remain on the board as a director.

The appointment comes following the commercial launch of Pyrukynd, its treatment for hemolytic anemia in adults with the rare, inherited disease pyruvate kinase deficiency and the company works to advance late-stage programs in sickle cell disease and thalassemia.

“Agios has engaged in deliberate and thoughtful long-term planning to drive positive impact for our people and patients. The team’s consistent execution—reflected in the divestiture of our oncology portfolio, the approval of our first genetically defined disease medicine and the initiation of pivotal trials in thalassemia and sickle cell disease—put Agios in a position of strength and great promise for the future,” said Fouse. “The time is right to evolve our leadership and deepen our genetically defined disease skill set to further drive our ability to develop life-changing treatments.”

She said Goff’s track record of leading rare disease product launches to drive their impact for patients, and scaling companies’ rare disease capabilities make him the right leader for Agios.

Goff joins Agios with more than thirty years of experience in the biopharmaceutical industry. Most recently he was executive vice president, chief commercial and global operations officer at Alexion Pharmaceuticals, where he was responsible for leading the global commercial and operations teams prior to the company’s acquisition by AstraZeneca in July 2021. Before joining Alexion, Goff was chief operating officer and a member of the board of directors of Neurovance.

Prior to joining Neurovance, Goff served as Baxalta’s executive vice president and president of the hematology division. He previously served with Baxter Healthcare Corporation as global hemophilia franchise head. Earlier in his career, he held positions of increasing responsibility in sales and marketing with Novartis Pharmaceuticals and the pharmaceutical division of Johnson & Johnson.

Goff has an MBA from the Wharton School at the University of Pennsylvania and a Bachelor of Arts from Skidmore College.

Author: Rare Daily Staff

Stay Connected

Sign up for updates straight to your inbox.